Scholars Central

Conference abstractPublished 14 Apr 2025

Developing evidence for biosimilar: Current implications and future perspective

Authors: Xie Bingjie

Guizhou University, China

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

In contrast to generic medicines, it is not possible to manufacture similar copy of an innovator product. Therefore, biosimilars are "similar but not the same" or in other words biosimilars are "the twin but not the clone" to the original biologic innovator product. Therefore the field of biosimilars presents several important challenges, including a) Verification of the similarity b) The interchangeability of biosimilars and innovator products c) Commercial opportunities as well as guidelines to assist manufacturers in product development d) Regulatory framework e) The possible need for unique naming to differentiate the various biopharmaceutical products f) Intellectual property rights and g) Public safety

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Bioanalysis & Biomedicine.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioanalysis & Biomedicine
  • BylineArticles whose byline prints “Xie Bingjie”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels